Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

This commentary argues that while cutaneous adverse effects are associated with better outcomes among patients undergoing treatment with pembrolizumab, further analysis is required to determine whether nonvitiligo cutaneous adverse effects contribute to the observed outcome.